1. Home
  2. RENX vs AZTR Comparison

RENX vs AZTR Comparison

Compare RENX & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenX Enterprises Corp. Common Stock

RENX

RenX Enterprises Corp. Common Stock

N/A

Current Price

$0.13

Market Cap

2.0M

Sector

N/A

ML Signal

N/A

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.17

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RENX
AZTR
Founded
2021
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
1.9M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
RENX
AZTR
Price
$0.13
$0.17
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
40.1M
1.5M
Earning Date
01-01-0001
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.14
52 Week High
$0.35
$1.40

Technical Indicators

Market Signals
Indicator
RENX
AZTR
Relative Strength Index (RSI) 41.22 35.69
Support Level N/A $0.15
Resistance Level $0.17 $0.32
Average True Range (ATR) 0.04 0.02
MACD -0.00 0.00
Stochastic Oscillator 2.52 30.82

Price Performance

Historical Comparison
RENX
AZTR

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: